- Home
- PHAR vs FCBC Comparison
PHAR vs FCBC Comparison
Compare PHAR & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- FCBC
- Stock Information
- Founded
- PHAR 1988
- FCBC 1874
- Country
- PHAR Netherlands
- FCBC United States
- Employees
- PHAR N/A
- FCBC 583
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- FCBC Major Banks
- Sector
- PHAR Health Care
- FCBC Finance
- Exchange
- PHAR Nasdaq
- FCBC Nasdaq
- Market Cap
- PHAR 718.1M
- FCBC 681.6M
- IPO Year
- PHAR N/A
- FCBC 1992
- Fundamental
- Price
- PHAR $10.45
- FCBC $37.76
- Analyst Decision
- PHAR Strong Buy
- FCBC Hold
- Analyst Count
- PHAR 3
- FCBC 1
- Target Price
- PHAR $30.00
- FCBC $38.00
- AVG Volume (30 Days)
- PHAR 2.6K
- FCBC 57.2K
- Earning Date
- PHAR 07-31-2025
- FCBC 07-22-2025
- Dividend Yield
- PHAR N/A
- FCBC 8.78%
- EPS Growth
- PHAR N/A
- FCBC 3.83
- EPS
- PHAR N/A
- FCBC 2.74
- Revenue
- PHAR $320,708,000.00
- FCBC $162,590,000.00
- Revenue This Year
- PHAR $13.31
- FCBC $2.34
- Revenue Next Year
- PHAR $7.68
- FCBC $1.10
- P/E Ratio
- PHAR N/A
- FCBC $13.73
- Revenue Growth
- PHAR 24.13
- FCBC 1.13
- 52 Week Low
- PHAR $6.65
- FCBC $33.37
- 52 Week High
- PHAR $12.61
- FCBC $49.02
- Technical
- Relative Strength Index (RSI)
- PHAR 47.51
- FCBC 47.88
- Support Level
- PHAR $10.41
- FCBC $36.81
- Resistance Level
- PHAR $11.50
- FCBC $37.79
- Average True Range (ATR)
- PHAR 0.32
- FCBC 0.75
- MACD
- PHAR -0.17
- FCBC -0.05
- Stochastic Oscillator
- PHAR 2.26
- FCBC 40.25
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.